Evidence map›Paper›PMID 40457134›Full record

ReviewMedical oncology (Northwood, London, England)2025

Targeting endothelial growth factor receptor in thyroid cancer: current concepts and future directions.

Nastaran Masoudi-Khoram, Sara Cheraghi, Mahboobeh Nazari, Mohammad E Khamseh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nastaran Masoudi-KhoramCancer Control Research Center, Cancer Control Foundation, Iran University of Medical Sciences, Tehran, Iran.
Sara CheraghiEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
Mahboobeh NazariMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran. nazari1980azar@yahoo.com.
Mohammad E KhamsehEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer (TC) ranks among the most prevalent cancers globally. The incidence rate of thyroid cancer has significantly risen in the past few decades. Most patients with differentiated thyroid cancer can be effectively treated with thyroidectomy and radioiodine adjuvant therapy. However, the management of locally advanced or distant metastatic TC remains challenging, especially in radioactive iodine-resistant tumors. Targeted therapy is the use of drugs designed to target overexpressed molecules in cancer cells. Epidermal growth factor receptor (EGFR) is a cell surface protein that plays a crucial role in cell proliferation, differentiation, and migration. Several studies have indicated that EGFR is overexpressed in thyroid cancer, making it a promising target in cancer treatment. In this review, we aimed to provide the functional significance of EGFR signaling pathway in TC. In addition, current strategies using anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors for treating thyroid cancer are explored.

Indexed as

ErbB ReceptorsMolecular Targeted TherapyProtein Kinase InhibitorsThyroid NeoplasmsHumansSignal TransductionEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsEGFRMonoclonal antibodyThyroid cancerTyrosine kinase inhibitor

Identifiers

PMID40457134

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.